SLS is a Stockholm regenerative-medicine clinic led by Dr. Torbjörn Ogéus. Agewell’s founder paid 29,500 SEK for 3 exosome and 5 PRF treatments across 4 treatment sites and rates the clinical experience highly. This review covers what was done, what it cost and what the wider evidence can and cannot show.
Agewell’s founder completed treatment at SLS and paid exactly 29,500 SEK in summer 2025 for 3 exosome and 5 PRF treatments across 4 treatment sites. This profile combines that first-hand record with information published by SLS and independent medical and regulatory sources. Personal experience and wider evidence are clearly labelled.
“Based on our founder’s experience, SLS delivered specialist-led care and a meaningful improvement in function. That is one person’s result, not proof that exosome or PRF treatment will work for others. Book only after a physician explains the product, expected benefit, alternatives, risks and rehabilitation plan.”
The short answer
Clinic locations
Apply Agewell’s 8-point evidence checklist to this clinic →
Programs, visits and memberships the clinic lists publicly, with prices, inclusions, caveats and sources.
Published figures are starting prices. Ask the clinic for a dated, itemized total covering mandatory extras, follow-up and cancellation terms.
Starting price only
How we checked this profile
Agewell records public prices, what each clinic provides, clinician involvement, follow-up and unanswered questions separately. Every factual statement links to the source that supports it. Information supplied by a clinic is labelled and does not change our editorial verdict without independent support.
PRF from 7,500 SEK for tendons or 20,000 SEK for joints; full-course and add-on costs vary
A complete treatment-course price including follow-up and add-on procedures is not publicly available.
Procedure course. Course completed in summer 2025 in the founder case.
PRF/PRP, stem-cell-adjacent treatment, HBOT, physio and chiropractic
Physician-led assessment and procedures. Direct clinician time was not published in a comparable format.
The founder case included a treatment course; the written rehab plan and complication reporting still need confirmation.
We did not find comparable published results or complication data in the sources reviewed.
For exosome or stem-cell treatments, what exact product is used, which outcomes and adverse events are published, and when should treatment stop?
SLS, Stockholms Led- & Smärtspecialist, is based at Karlavägen 1 in Stockholm and positions itself around modern non-surgical pain treatment. Its published services include PRF/PRP, stem-cell treatment, HBOT, chiropractic and physiotherapy, and Arthrosamid for knee osteoarthritis.
The clinic presents Dr. Torbjörn Ogéus as a leading voice in regenerative medicine and says he has published more than 14 peer-reviewed studies in regenerative medicine and stem cells. SLS also publishes a research page covering PRF, SVF, exosomes, osteoarthritis and tendon-pain case series.
In summer 2025, Agewell’s founder paid 29,500 SEK for a course comprising 3 exosome treatments and 5 PRF treatments across 4 treatment sites for long-running tennis elbow, big-toe joint pain, running-limiting lower-limb pain and wrist pain. The premises were simple; the treatment experience felt premium, careful and specialist-led.
He reports meaningful improvement in pain, function and strength performance afterwards, including a sharp rebound in bench press that he attributes to better tendon and ligament recovery. That is a first-person outcome, not controlled proof, so we treat it as a strong experience signal rather than clinical evidence.
The fit is clearest for someone with chronic orthopedic pain who has already spent time and money on rehab, chiropractic work or conservative care and now wants a physician-led regenerative option with the uncertainty made explicit.
At 29,500 SEK in the summer 2025 founder case, this was not cheap wellness. It can still be rationally priced if the alternative is years of unresolved pain, repeated appointments and lost training capacity. The historical founder-paid total is not a current quote or a typical-patient price.
Regenerative medicine is not a normal aging-well purchase. Ask what product is being injected, where it came from, how sterility and storage are handled, whether imaging guidance is used, how complications are managed, and what rehab plan follows the procedure.
Regulatory status varies by country and product. As a safety benchmark, the U.S. FDA warns that many regenerative products, including stem cells, stromal vascular fraction, ortho-biologics and exosomes, are marketed without approval for orthopedic conditions. That warning should not be ignored just because the clinic experience is strong.
Skip it if you expect guaranteed cartilage regrowth, a performance boost or biological reversal from a treatment package. Also skip if there is no diagnosis, no physician accountability, no clear consent discussion, or no tolerance for uncertain evidence.
Consider it if the problem is specific, chronic, orthopedic, costly in daily life, and you can evaluate it with a serious clinician instead of buying hope from a brochure.
Agewell’s founder reported meaningful improvement after a summer 2025 SLS course comprising 3 exosome treatments and 5 PRF treatments across 4 treatment sites for chronic tendon and joint pain. Treat that as a strong first-person outcome, not clinical proof; results depend on diagnosis, protocol, rehab and individual biology.
SLS positions exosomes as part of physician-led regenerative treatment for orthopedic and pain problems. The practical question is not just "do exosomes work?" but what product is used, how it is handled, whether imaging guidance is used, what consent says and what rehab plan follows.
SLS publishes PRF from 7,500 SEK for tendon treatment and from 20,000 SEK for joint treatment. Agewell’s separate founder case cost exactly 29,500 SEK in summer 2025 for 3 exosome treatments and 5 PRF treatments across 4 treatment sites. That historical case is not a current standard quote; confirm the protocol, number of sessions and follow-up before booking.
Not in the simple consumer sense. SLS has specialist depth and published research material, but stem-cell-adjacent and exosome therapies still require a physician-led risk discussion because regulatory status and evidence quality vary by treatment and indication.
SLS is most interesting for a specific, chronic orthopedic problem where conservative care has not solved the issue and the cost of doing nothing is real. It is not the right fit for someone buying vague aging claims, guaranteed cartilage regrowth or a performance shortcut.
By David Persson · Profile updated 2026-07-15 · Information last checked 2026-07-15 · Prices can change; confirm with the clinic · Work with this clinic? Submit an update
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.